Biosensor buys Cardiac Science's diagnostic line:
This article was originally published in Clinica
Executive Summary
Biosensor has bought Cardiac Science's diagnostic monitoring product line. Columbia-based Biosensor will assume liabilities totalling around $110,000, and will issue Cardiac with 1.44 million shares, which represent 7.7% of the voting shares in Biosensor. Biosensor will gain Cardiac's Holter monitor and ECG product line and will add qualified distributors in over 40 countries. Irvine, California-based Cardiac Science plans to focus on its defibrillation technology.